Back to Faculty List
RESEARCH OVERVIEW
Dr. Brad Spellberg is an infectious disease specialist whose research focuses on developing vaccines and immune therapies for lethal, drug resistant infections. He has also worked closely with the Infectious Diseases Society of America (IDSA) to bring attention to the converging public health crises of skyrocketing antibiotic resistance and plummeting new antibiotic development.
Read more »
EDUCATION
- B.A., 1994, Immunology-Molecular Cell Biology, UC Berkeley
- M.D., 1999, University Of California, Los Angeles, School Of Medicine
- Residency, 2002, Internal Medicine, Harbor-UCLA Medical Center
- Fellowship, 2004, Infectious Disease, Harbor-UCLA Medical Center
ACADEMIC APPOINTMENTS
- Associate Professor of Medicine, David Geffen School of Medicine
- Division of General Internal Medicine, LA BioMed at Harbor-UCLA Medical Center
- Associate Program Director for Internal Medicine Residency Training Program, Harbor-UCLA Medical Center
- Associate Medical Director for Inpatient Services, Harbor-UCLA Medical Center
AWARDS & RECOGNITIONS
- 1994: Phi Beta Kappa as a Junior
- 1994: Highest Honors (Summa Cum Laude) at UC Berkeley
- 1998: Elected Alpha Omega Alpha as an MS III
- 1998-1999: UCLA Alpha Omega Alpha Chapter Co-President
- 1999: Stafford Warren Award for Top Academic Performance at the UCLA School of Medicine
- 2004: Harbor-UCLA Department of Medicine Subspecialty Fellow of the Yea
- 2007: LA Biomedical Research Institute Liu Young Investigator’s Award
- 2007: Fellow, Infectious Diseases Society of America
- 2010: Outstanding Academic Title Award for Rising Plague, Choice Magazine
- 2010: Fellow, American College of Physicians
- 2011: Kouichi R. Tanaka Distinguished Faculty Teaching Award, Harbor-UCLA Dept. of Medicine
PUBLICATIONS
Recent and/or Significant Studies:
- The Critical Impact of Time Discounting on Economic Incentives to Overcome the Antibiotic Market Failure. Spellberg B, Sharma P, Rex J. Nat Rev Drug Discovery. 2012. 11:168.
- Active and Passive Immunization Protects against Lethal, Extreme Drug Resistant-Acinetobacter baumannii Infection. Luo G, Lin L, Ibrahim AS, Baquir B, Pantapalangkoor P, Bonomo RA, Doi Y, Adams MD, Russo TA, Spellberg B. PLoS One. 2012. 7(1): e29446.
- LpxC Inhibition Protects Mice from Resistant Acinetobacter baumannii by Modulating Inflammation and Enhancing Phagocytosis. Lin L, Tan B, Pantapalangkoor P, Ho T, Baquir B, Tomaras A, Montgomery JI, Reilly U, Barbacci EG, Hujer K, Bonomo RA, Fernandez L, Hancock REW, Adams MD, French SW, Buslon VS, Spellberg B. mBio. 2012. e00312-12
- The future of antibiotics and resistance. Spellberg B, Bartlett JG, Gilbert DN. N Engl J Med. 2013 Jan 24;368(4):299-302.